ArticleFrontiers in neurology2026
The clinical features of anti-CNTN1 antibodies associated autoimmune nodopathies with nephropathy: a case series.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The concurrence of anti-contactin-1 (CNTN1) antibody-associated autoimmune nodopathies (AN) and nephropathy has been sporadically reported, though the underlying relationship remains unclear. This case series study aimed to investigate the clinical characteristics and renal pathology of anti-CNTN1 antibody-associated AN with nephropathy. Methods: A retrospective case series was conducted including 69 patients diagnosed with AN, among whom 11 patients tested positive for anti-CNTN1 antibodies. Clinical manifestations, electrophysiological data, laboratory results, and renal biopsy findings were collected and analyzed. The presence of nodal/paranodal antibodies was confirmed using serum cell-based assays. Renal biopsies were performed in four patients, with immunohistochemical and immunofluorescence staining, including CNTN1 staining, to characterize renal pathology. Results: Compared to patients with non-anti-CNTN1 antibody-associated AN, the anti-CNTN1 antibody group had a significantly lower proportion of males (54.5% vs. 84.5%, Conclusion: Anti-CNTN1 antibody-associated AN patients have a higher prevalence of nephropathy compared to those AN without anti-CNTN1 antibodies. Females demonstrate a particularly higher risk of comorbid AN and nephropathy. Renal pathology in these patients is not limited to MN but can also include LN. These findings highlight a complex immunopathological relationship between anti-CNTN1 antibody-associated AN and nephropathy, warranting further studies to understand the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.